伊斑膦酸钠对前列腺癌骨转移患者去势治疗后骨密度的影响

目的 评估伊斑膦酸钠对前列腺癌骨转移患者药物去势治疗后骨密度的影响。方法 晚期前列腺癌患者30例，给予最大雄激素阻断治疗，随机分为两组，治疗组15例给予伊斑膦酸钠治疗（4 mg，每月一次，静脉滴注），对照组15例未给予伊斑膦酸钠治疗。两组患者去势治疗前骨密度指标差异无统计学意义（P>0.05）；观察去势治疗后3、6和12月时的骨密度变化。结果 治疗3月时，两组患者骨密度指标均有下降，但差异无统计学意义（P>0.05）；6月时，治疗组骨密度增加，对照组骨密度下降，差异仍无统计学意义（P>0.05）；12月时，骨密度差异有统计学意义（P=0.001）。结论 前列腺癌患者接受药物去势治疗后12月时其骨密度较治疗前明显降低，而伊斑膦酸钠可减缓前列腺癌患者接受药物去势治疗后骨密度下降，减少骨丢失。

Effects of Ibandronic Acid Sodium on Bone Mineral Density of Prostate Cancer Patients#br# with Bone Metastasis after Androgen Deprivation Therapy

Objective To evaluate the effects of ibandronic acid sodium on bone mineral density (BMD) ofprostate cancer patients with bone metastasis after androgen deprivation therapy. Methods Thirty casesof advanced prostate cancer patients were recruited in this study and received maximal androgen blockadetherapy. Fifteen patients were randomized into the treatment group and received intravenous ibandronic acidsodium (4 mg, once a month, intravenous drip), and the other 15 patients were in the control group withoutibandronic acid sodium treatment. There was no statistical difference in BMD index between two groupsbefore androgen deprivation therapy. BMD of the lumber spine (L2-3) and the femoral neck were measuredby dual-energy X-ray absorptiometry after 3, 6 and 12 months of treatment, respectively. Results After 3months of treatment, BMD value was decreased in both group and there was no statistical difference(P>0.05).After 6 months, BMD was increased in the treatment group while decreased in the control group, and still withno statistical difference（P>0.05）. After 12 months, the difference in both groups was statistically different(P=0.001). Conclusion The BMD in prostate cancer patients was signifi cantly decreased after 12 months ofandrogen deprivation therapy, while ibandronic acid sodium could retard the decrease.